Watch TRAX. Know when insiders buy.
One email the day a filing lands. Free.
TRAX
First Tracks Biotherapeutics, Inc.
41.25
+4.97 +13.70%
USD · close Oct 20
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
33
FLAG · insiders 25, shorts 41
Insiders, 90 days
−$1.8M
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
FINANCIALS: NOT YET PULLED FROM SEC XBRL, CHECK BACK AFTER TONIGHT52W 15.32 – 47.92
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$34.9M | −$33.4M | — | -0.95 | −$31.9M | $25K | −$31.9M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$52.8M | −$50.5M | — | — | −$32.6M | $17K | −$32.6M | Aug 12 |
| Q2 2025 · Jun 30 | — | — | — | −$45.9M | −$42.4M | — | -1.47 | −$38.6M | $39K | −$38.7M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$51.3M | −$47.2M | — | — | −$45M | $35K | −$45M | Aug 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|
Every number comes from First Tracks Biotherapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.